Earnings Feed
Start Free
Home/Filings/4/0001654954-18-011239
4//SEC Filing

Gelbfish Gary A. 4

Accession 0001654954-18-011239

CIK 0001410098other
View on SEC.govCompany Profile

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 5:07 PM ET

Size

18.7 KB

Accession

0001654954-18-011239

Insider Transaction Report

Form 4
Period: 2018-10-12
CorMedix Inc.CRMD
Gelbfish Gary A.
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2018-10-12$1.05/sh+1,000,000$1,050,000→ 3,101,121 total
  • Exercise/Conversion

    Series B Common Stock Warrant

    2018-10-12−1,000,000→ 0 total
    Exercise: $1.05→ Common Stock, $0.001 par value per share (1,000,000 underlying)
  • Tax Payment

    Common Stock

    2018-10-12$2.24/sh−468,750$1,050,000→ 2,632,371 total
  • Other

    Series A Common Stock Warrant

    2018-09-10−1,000,000→ 0 total
    Exercise: $0.75→ Common Stock, $0.001 par value per share (1,000,000 underlying)
Holdings

  • Stock Option (Right to Buy Common Stock)

    Exercise: $0.37Exp: 2027-08-03→ Common Stock, $0.001 par value per share (75,000 underlying)
    75,000

  • Warrant (Right to Purchase Common Stock)

    Exercise: $0.90From: 2015-01-08Exp: 2020-01-01→ Common Stock, $0.001 par value per share (250,000 underlying)
    250,000

  • Common Stock

    (indirect: By Foundation)
    14,000

  • Stock Option (Right to Buy Common Stock)

    Exercise: $0.57Exp: 2028-02-16→ Common Stock, $0.001 par value per share (40,000 underlying)
    40,000

  • Series C-3 Non-Voting Convertible Preferred Stock

    From: 2014-01-08→ Common Stock, $0.001 par value per share (500,000 underlying)
    500,000

  • Restricted Stock Units

    → Common Stock, $0.001 par value per share (10,000 underlying)
    10,000
Footnotes (7)
  • [F1]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
  • [F2]The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date.
  • [F3]The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018..
  • [F4]These options were granted on 2/16/2018. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
  • [F5]These Restricted Stock Units were granted on 2/16/2018. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest in full on the first anniversary of the date of grant, subject to continued service on the board.
  • [F6]These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
  • [F7]The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.

Documents

1 file

Issuer

CorMedix Inc.

CIK 0001410098

→
Entity typeother

Related Parties

1
  • filerCIK 0001488011

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 5:07 PM ET
Size
18.7 KB
View on SEC.gov